Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

The effects of aerobic training on subclinical negative affect: A randomized controlled trial.

McIntyre KM, Puterman E, Scodes JM, Choo TH, Choi CJ, Pavlicova M, Sloan RP.

Health Psychol. 2020 Jan 9. doi: 10.1037/hea0000836. [Epub ahead of print]

PMID:
31916828
2.

A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial.

Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, Nunes EV.

Am J Psychiatry. 2019 Dec 2:appiajp201919070684. doi: 10.1176/appi.ajp.2019.19070684. [Epub ahead of print]

PMID:
31786934
3.

Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users.

Levin FR, Mariani JJ, Pavlicova M, Choi CJ, Mahony AL, Brooks DJ, Bisaga A, Dakwar E, Carpenter KM, Naqvi N, Nunes EV, Kampman K.

Drug Alcohol Depend. 2020 Jan 1;206:107700. doi: 10.1016/j.drugalcdep.2019.107700. Epub 2019 Nov 1.

PMID:
31753736
4.

Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.

Ruglass LM, Scodes J, Pavlicova M, Campbell ANC, Fitzpatrick S, Barbosa-Leiker C, Burlew K, Greenfield SF, Rotrosen J, Nunes EV Jr.

Drug Alcohol Depend. 2019 Dec 1;205:107649. doi: 10.1016/j.drugalcdep.2019.107649. Epub 2019 Oct 21.

PMID:
31704382
5.

DSM-5 substance use disorder symptom clusters and HIV antiretroviral therapy (ART) adherence.

Paschen-Wolff MM, Campbell ANC, Tross S, Choo TH, Pavlicova M, Jarlais DD.

AIDS Care. 2019 Nov 4:1-6. doi: 10.1080/09540121.2019.1686600. [Epub ahead of print]

PMID:
31682153
6.

Understanding site variability in a multisite clinical trial of a technology-delivered psychosocial intervention for substance use disorders.

Vaezazizi LM, Campbell ANC, Pavlicova M, Hu MC, Nunes EV.

J Subst Abuse Treat. 2019 Oct;105:64-70. doi: 10.1016/j.jsat.2019.03.003. Epub 2019 Mar 13.

PMID:
31443894
7.

Guanfacine extended-release for cannabis use disorder: a pilot feasibility trial.

Dakwar E, Mahony A, Choi CJ, Pavlicova M, Brooks D, Mariani JP, Levin FR.

Am J Drug Alcohol Abuse. 2020;46(1):44-48. doi: 10.1080/00952990.2019.1620259. Epub 2019 Jul 24.

8.

Development of a prognostic tool exploring female adolescent risk for HIV prevention and PrEP in rural South Africa, a generalised epidemic setting.

Ayton SG, Pavlicova M, Tamir H, Abdool Karim Q.

Sex Transm Infect. 2019 Jul 20. pii: sextrans-2019-054067. doi: 10.1136/sextrans-2019-054067. [Epub ahead of print]

PMID:
31326947
9.

Utility of 3D Printed Cardiac Models for Medical Student Education in Congenital Heart Disease: Across a Spectrum of Disease Severity.

Smerling J, Marboe CC, Lefkowitch JH, Pavlicova M, Bacha E, Einstein AJ, Naka Y, Glickstein J, Farooqi KM.

Pediatr Cardiol. 2019 Aug;40(6):1258-1265. doi: 10.1007/s00246-019-02146-8. Epub 2019 Jun 25.

PMID:
31240370
10.

A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.

Dakwar E, Nunes EV, Hart CL, Foltin RW, Mathew SJ, Carpenter KM, Choi CJJ, Basaraba CN, Pavlicova M, Levin FR.

Am J Psychiatry. 2019 Nov 1;176(11):923-930. doi: 10.1176/appi.ajp.2019.18101123. Epub 2019 Jun 24.

PMID:
31230464
11.

Social functioning outcomes among individuals with substance use disorders receiving internet-delivered community reinforcement approach.

Marino LA, Campbell ANC, Pavlicova M, Hu M, Nunes EV.

Subst Use Misuse. 2019;54(7):1067-1074. doi: 10.1080/10826084.2018.1528458. Epub 2019 Mar 8.

PMID:
30849925
12.

Anger-reduction treatment reduces negative affect reactivity to daily stressors.

McIntyre KM, Mogle JA, Scodes JM, Pavlicova M, Shapiro PA, Gorenstein EE, Tager FA, Monk C, Almeida DM, Sloan RP.

J Consult Clin Psychol. 2019 Feb;87(2):141-150. doi: 10.1037/ccp0000359. Epub 2018 Dec 3.

PMID:
30507214
13.

Aerobic Exercise Training and Inducible Inflammation: Results of a Randomized Controlled Trial in Healthy, Young Adults.

Sloan RP, Shapiro PA, McKinley PS, Bartels M, Shimbo D, Lauriola V, Karmally W, Pavlicova M, Choi CJ, Choo TH, Scodes JM, Flood P, Tracey KJ.

J Am Heart Assoc. 2018 Sep 4;7(17):e010201. doi: 10.1161/JAHA.118.010201.

14.

A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.

Sullivan MA, Bisaga A, Pavlicova M, Carpenter KM, Choi CJ, Mishlen K, Levin FR, Mariani JJ, Nunes EV.

Am J Psychiatry. 2019 Feb 1;176(2):129-137. doi: 10.1176/appi.ajp.2018.17070732. Epub 2018 Oct 19.

15.

Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial.

Campbell ANC, Barbosa-Leiker C, Hatch-Maillette M, Mennenga SE, Pavlicova M, Scodes J, Saraiya T, Mitchell SG, Rotrosen J, Novo P, Nunes EV, Greenfield SF.

Am J Addict. 2018 Sep;27(6):465-470. doi: 10.1111/ajad.12784. Epub 2018 Aug 14.

16.

Cognitive functioning and treatment outcomes in a randomized controlled trial of internet-delivered drug and alcohol treatment.

Shulman M, Campbell A, Pavlicova M, Hu MC, Aharonovich E, Nunes EV.

Am J Addict. 2018 Sep;27(6):509-515. doi: 10.1111/ajad.12769. Epub 2018 Aug 9.

17.

How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis.

Levin FR, Choi CJ, Pavlicova M, Mariani JJ, Mahony A, Brooks DJ, Nunes EV, Grabowski J.

Drug Alcohol Depend. 2018 Jul 1;188:135-140. doi: 10.1016/j.drugalcdep.2018.03.043. Epub 2018 May 1.

18.

Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder.

Brezing CA, Choi CJ, Pavlicova M, Brooks D, Mahony AL, Mariani JJ, Levin FR.

Am J Addict. 2018 Mar;27(2):101-107. doi: 10.1111/ajad.12660. Epub 2018 Feb 19.

19.

Open-label pilot study of injectable naltrexone for cannabis dependence.

Notzon DP, Kelly MA, Choi CJ, Pavlicova M, Mahony AL, Brooks DJ, Mariani JJ, Levin FR.

Am J Drug Alcohol Abuse. 2018;44(6):619-627. doi: 10.1080/00952990.2017.1423321. Epub 2018 Feb 8.

20.

A Randomized Controlled Trial of Medication and Cognitive-Behavioral Therapy for Hypochondriasis.

Fallon BA, Ahern DK, Pavlicova M, Slavov I, Skritskya N, Barsky AJ.

Am J Psychiatry. 2017 Aug 1;174(8):756-764. doi: 10.1176/appi.ajp.2017.16020189. Epub 2017 Jun 29.

21.

Sociodemographic and Substance Use Disorder Determinants of HIV Sexual Risk Behavior in Men and Women in Outpatient Drug Treatment in the NIDA National Drug Abuse Treatment Clinical Trials Network.

Kidd JD, Tross S, Pavlicova M, Hu MC, Campbell ANC, Nunes EV.

Subst Use Misuse. 2017 Jun 7;52(7):858-865. doi: 10.1080/10826084.2016.1264971. Epub 2017 Feb 8.

22.

Racial/ethnic subgroup differences in outcomes and acceptability of an Internet-delivered intervention for substance use disorders.

Campbell ANC, Montgomery L, Sanchez K, Pavlicova M, Hu M, Newville H, Weaver L, Nunes EV.

J Ethn Subst Abuse. 2017 Oct-Dec;16(4):460-478. doi: 10.1080/15332640.2017.1300550. Epub 2017 Apr 3.

23.

Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.

Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM, Levin FR, Dakwar E, Mariani JJ, Nunes EV.

Am J Psychiatry. 2017 May 1;174(5):459-467. doi: 10.1176/appi.ajp.2016.16050548. Epub 2017 Jan 10.

24.

Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence.

Notzon DP, Mariani JJ, Pavlicova M, Glass A, Mahony AL, Brooks DJ, Grabowski J, Levin FR.

Am J Addict. 2016 Dec;25(8):666-672. doi: 10.1111/ajad.12467. Epub 2016 Nov 11.

25.

Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial.

Lévesque A, Campbell AN, Pavlicova M, Hu MC, Walker R, McClure EA, Ghitza UE, Bailey G, Stitzer M, Nunes EV.

Addict Behav. 2017 Feb;65:74-80. doi: 10.1016/j.addbeh.2016.09.012. Epub 2016 Sep 30.

26.

Barriers to Condom Use: Results for Men and Women Enrolled in HIV Risk Reduction Trials in Outpatient Drug Treatment.

Campbell AN, Brooks AJ, Pavlicova M, Hu MC, Hatch-Maillette MA, Calsyn DA, Tross S.

J HIV AIDS Soc Serv. 2016;15(2):130-146.

27.
28.

Antiretroviral medication treatment for all HIV-infected individuals: a protocol using innovative multilevel methodologies to evaluate New York City's universal ART policy among problem substance users.

Campbell AN, Des Jarlais D, Hannah C, Braunstein S, Tross S, Kersanske L, Borges C, Pavlicova M, Jefferson K, Newville H, Weaver L, Wolff M.

BMC Health Serv Res. 2016 Aug 2;16(a):341. doi: 10.1186/s12913-016-1554-8.

29.

ADHD Is Highly Prevalent in Patients Seeking Treatment for Cannabis Use Disorders.

Notzon DP, Pavlicova M, Glass A, Mariani JJ, Mahony AL, Brooks DJ, Levin FR.

J Atten Disord. 2016 Mar 31. pii: 1087054716640109. [Epub ahead of print]

30.

Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.

Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, Nunes EV, Bisaga A, Dakwar E, Carpenter KM, Sullivan MA, Choi JC.

Drug Alcohol Depend. 2016 Feb 1;159:53-60. doi: 10.1016/j.drugalcdep.2015.11.025. Epub 2015 Nov 27.

31.

Substance Use, Depression and Sociodemographic Determinants of HIV Sexual Risk Behavior in Outpatient Substance Abuse Treatment Patients.

Tross S, Feaster DJ, Thorens G, Duan R, Gomez Z, Pavlicova M, Hu MC, Kyle T, Erickson S, Spector A, Haynes L, Metsch LR.

J Addict Med. 2015 Nov-Dec;9(6):457-63. doi: 10.1097/ADM.0000000000000162.

32.

Comparison of 2 Measures of HIV Sexual Risk Behavior in Women in Outpatient Drug Treatment Programs.

Thorens G, Pavlicova M, Hu MC, Nunes EV, Campbell AN, Tross S.

J Addict Med. 2015 Nov-Dec;9(6):454-6. doi: 10.1097/ADM.0000000000000159.

33.

Contingency Management Abstinence Incentives: Cost and Implications for Treatment Tailoring.

Cunningham C, Stitzer M, Campbell AN, Pavlicova M, Hu MC, Nunes EV.

J Subst Abuse Treat. 2017 Jan;72:134-139. doi: 10.1016/j.jsat.2015.08.010. Epub 2015 Sep 21.

34.

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN, Levin FR, Carpenter KM, Mariani JJ, Nunes EV.

Drug Alcohol Depend. 2015 Sep 1;154:38-45. doi: 10.1016/j.drugalcdep.2015.05.013. Epub 2015 Jul 8.

35.

The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.

Cooper ZD, Johnson KW, Pavlicova M, Glass A, Vosburg SK, Sullivan MA, Manubay JM, Martinez DM, Jones JD, Saccone PA, Comer SD.

Addict Biol. 2016 Jul;21(4):895-903. doi: 10.1111/adb.12261. Epub 2015 May 14.

36.

Baseline characteristics of patients predicting suitability for rapid naltrexone induction.

Mogali S, Khan NA, Drill ES, Pavlicova M, Sullivan MA, Nunes E, Bisaga A.

Am J Addict. 2015 Apr;24(3):258-64. doi: 10.1111/ajad.12180.

37.

Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.

Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD.

Neuropsychopharmacology. 2015 Oct;40(11):2489-98. doi: 10.1038/npp.2015.108. Epub 2015 Apr 16.

38.

Gender-based Outcomes and Acceptability of a Computer-assisted Psychosocial Intervention for Substance Use Disorders.

Campbell AN, Nunes EV, Pavlicova M, Hatch-Maillette M, Hu MC, Bailey GL, Sugarman DE, Miele GM, Rieckmann T, Shores-Wilson K, Turrigiano E, Greenfield SF.

J Subst Abuse Treat. 2015 Jun;53:9-15. doi: 10.1016/j.jsat.2014.12.006. Epub 2014 Dec 30.

39.

Cigarette Smoking During Substance Use Disorder Treatment: Secondary Outcomes from a National Drug Abuse Treatment Clinical Trials Network study.

McClure EA, Campbell AN, Pavlicova M, Hu M, Winhusen T, Vandrey RG, Ruglass LM, Covey LS, Stitzer ML, Kyle TL, Nunes EV.

J Subst Abuse Treat. 2015 Jun;53:39-46. doi: 10.1016/j.jsat.2014.12.007. Epub 2014 Dec 30.

40.

Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.

Sullivan MA, Bisaga A, Glass A, Mishlen K, Pavlicova M, Carpenter KM, Mariani JJ, Levin FR, Nunes EV.

Drug Alcohol Depend. 2015 Feb 1;147:122-9. doi: 10.1016/j.drugalcdep.2014.11.028. Epub 2014 Dec 9.

41.

Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?

Kelly MA, Pavlicova M, Glass A, Mariani JJ, Bisaga A, Sullivan MA, Nunes EV, Levin FR.

Drug Alcohol Depend. 2014 Nov 1;144:42-6. doi: 10.1016/j.drugalcdep.2014.06.040. Epub 2014 Jul 11.

42.

A comparison of lyme disease serologic test results from 4 laboratories in patients with persistent symptoms after antibiotic treatment.

Fallon BA, Pavlicova M, Coffino SW, Brenner C.

Clin Infect Dis. 2014 Dec 15;59(12):1705-10. doi: 10.1093/cid/ciu703. Epub 2014 Sep 2.

PMID:
25182244
43.

Open-label pilot study of quetiapine treatment for cannabis dependence.

Mariani JJ, Pavlicova M, Mamczur AK, Bisaga A, Nunes EV, Levin FR.

Am J Drug Alcohol Abuse. 2014 Jul;40(4):280-4. doi: 10.3109/00952990.2014.884102.

44.

Dysregulation of diurnal cortisol secretion affects abstinence induction during a lead-in period of a clinical trial for depressed cocaine-dependent patients.

Raby WN, Sanfilippo L, Pavlicova M, Carpenter KM, Glass A, Onyemekwu C, Roginek E, Nunes EV.

Am J Addict. 2014 Jan-Feb;23(1):1-6. doi: 10.1111/j.1521-0391.2013.12060.x. Epub 2013 May 30.

45.

The painfulness of active, but not sham, transcranial magnetic stimulation decreases rapidly over time: results from the double-blind phase of the OPT-TMS Trial.

Borckardt JJ, Nahas ZH, Teal J, Lisanby SH, McDonald WM, Avery D, Durkalski V, Pavlicova M, Long JM, Sackeim HA, George MS.

Brain Stimul. 2013 Nov;6(6):925-8. doi: 10.1016/j.brs.2013.04.009. Epub 2013 May 21.

46.

Reducing heavy drinking in HIV primary care: a randomized trial of brief intervention, with and without technological enhancement.

Hasin DS, Aharonovich E, O'Leary A, Greenstein E, Pavlicova M, Arunajadai S, Waxman R, Wainberg M, Helzer J, Johnston B.

Addiction. 2013 Jul;108(7):1230-40. doi: 10.1111/add.12127. Epub 2013 Apr 17.

47.

A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.

Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, Bisaga A, Sullivan MA, Carpenter KM.

Addiction. 2013 Jun;108(6):1084-94. doi: 10.1111/add.12108. Epub 2013 Mar 21.

48.

The utility of attention-deficit/hyperactivity disorder screening instruments in individuals seeking treatment for substance use disorders.

Dakwar E, Mahony A, Pavlicova M, Glass A, Brooks D, Mariani JJ, Grabowski J, Levin FR.

J Clin Psychiatry. 2012 Nov;73(11):e1372-8. doi: 10.4088/JCP.12m07895.

49.

Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement.

Herron AJ, Mariani JJ, Pavlicova M, Parrinello CM, Bold KW, Levin FR, Nunes EV, Sullivan MA, Raby WN, Bisaga A.

Drug Alcohol Depend. 2013 Feb 1;128(1-2):77-82. doi: 10.1016/j.drugalcdep.2012.08.007. Epub 2012 Aug 22.

50.

Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial.

Mariani JJ, Pavlicova M, Bisaga A, Nunes EV, Brooks DJ, Levin FR.

Biol Psychiatry. 2012 Dec 1;72(11):950-6. doi: 10.1016/j.biopsych.2012.05.032. Epub 2012 Jul 12.

Supplemental Content

Loading ...
Support Center